|
|
| Company History |
| 2013 |
In November, DB Pharm and Zenics participate in the Annual Meeting of the
Korean Society of Anesthesiologists, Nov. 7-9, Kangwon Land. At the Meeting,
Caldolor® booth and exhibition are arranged
In October, DB Pharm and Zenics participate in the Annual Meeting of the
American Society of Anesthesiologists, Oct. 12-16, San Francisco.
At the Meeting, Caldolor® booth and exhibition are arranged and Caldolor®
studies are presented.
In September, DB Pharm participates in the 45th Congress of the International
Society of Pediatric Oncology, Sep.24-28, Hong Kong.
In September, DB Pharm achieves first commercial sales of Caldolor® (ibuprofen IV)
through local distributor, Zenics Korea.
In July, DB Pharm launches Caldolor®(ibuprofen IV) for the indications
for reduction of fever and management of moderate to severe pain as an adjunct
to opioid analgesics in Korea
In July, DB Pharm reaches Distribution Agreement with Zenics Korea for
Caldolor® (ibuprofen IV)
In June, DB Pharm receives HIRA decision on the reimbursement classification
of Caldolor® as non imbursement drug which means the drug cost would be covered by patient's oneself.
|
|
| 2012 |
In September, DB Pharm has changed representative director from K K Park &
H K Lee to H K Park
In June, DB Pharm participates in the Symposium of the Korean Burn Society, June 14-15, Kim Koo Memorial Hall. At the Meeting, Caldolor® booth and exhibition are arranged.
|
|
| 2011 |
In November, DB Pharm participates in the 52th Symposium of the Korean
Society of Hematology, Nov.11-12, Songdo Convensia. At the Meeting, Caldolor®
booth and exhibition are arranged.
In May, DB Pharm receives KFDA approval for Hospira Cytarabine 100mg
transferred from Pharma Research.
In January, DB Pharm receives KFDA approval for Caldolor® (ibuprofen IV), a worldwide brand named NSAIDs for pain and fever patients.
|
|
| 2009 |
In December, DB Pharm reaches License and Distribution Agreement with Cumberland
Pharmaceutical Inc. for the business of Caldolor® in Korea market.
In September, DB Pharm reaches Promotion Agency Agreement with Hospira for
three products {Cytarabine, Pentamidine & Nipent® (pentostatin)} for five years.
In June, H K Lee, representative director, visits Cumberland Pharmaceutical Inc. and has business
meeting with the CEO, Mr. A Z Kazimi, for the partnership of Cumberland products including Caldolor® (ibuprofen IV).
|
|
| 2007 |
DB Pharm reaches new License Agreement with Hospira,
an American multi-national company, for oncology & antidote injectables in Korea as Hospira acquired Mayne Pharma.
|
|
| 2004 |
DB Pharm receives KFDA approval for Anzatax® (paclitaxel), a worldwide brand named anti-cancer drug, and launches it for the patients of lung, breast & ovarian cancer |
|
| 2002 |
DB Pharm reaches new License Agreement with Mayne Pharma,
an Australian multi-national company, for oncology & antidote injectables in Korea as Mayne Pharma acquired F H Faulding. |
|
| 1999 |
DB Pharm Korea Co., Ltd. has established in Seoul.
The company has licenses for consulting, importing, trading & whole selling of drug and health food. The founders are K K Park and H K Lee.
|
|
| 1997 |
Chung Woo achieves product registration approval form KFDA for three
oncology products and one antidote and launched that in market under the name of HK Pharmed.
|
|
| 1996 |
Chung Woo Trading Company, predecessor of the present DB Pharm Korea Co., Ltd., reaches License Agreement with F H Faulding, an Australian multi-national company, for oncology & antidote injectables in Korea
|
|
|
